Skinvisible (SKVI) Common Equity (2016 - 2025)
Skinvisible (SKVI) has disclosed Common Equity for 16 consecutive years, with -$10.3 million as the latest value for Q4 2025.
- Quarterly Common Equity fell 11.27% to -$10.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$10.3 million through Dec 2025, down 11.27% year-over-year, with the annual reading at -$10.3 million for FY2025, 11.27% down from the prior year.
- Common Equity hit -$10.3 million in Q4 2025 for Skinvisible, down from -$10.0 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of -$4.9 million in Q1 2021 to a low of -$10.3 million in Q4 2025.
- Historically, Common Equity has averaged -$7.8 million across 5 years, with a median of -$8.6 million in 2023.
- Biggest five-year swings in Common Equity: plummeted 44.85% in 2023 and later fell 1.39% in 2025.
- Year by year, Common Equity stood at -$5.4 million in 2021, then dropped by 22.62% to -$6.6 million in 2022, then crashed by 35.88% to -$9.0 million in 2023, then dropped by 2.22% to -$9.2 million in 2024, then dropped by 11.27% to -$10.3 million in 2025.
- Business Quant data shows Common Equity for SKVI at -$10.3 million in Q4 2025, -$10.0 million in Q3 2025, and -$9.8 million in Q2 2025.